CAS 80937-31-1|Flosulide
Introduction：Basic information about CAS 80937-31-1|Flosulide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Flosulide | ||
|---|---|---|---|
| CAS Number | 80937-31-1 | Molecular Weight | 353.34100 |
| Density | 1.506g/cm3 | Boiling Point | 446.9ºC at 760 mmHg |
| Molecular Formula | C16H13F2NO4S | Melting Point | / |
| MSDS | / | Flash Point | 224.1ºC |
Names
| Name | N-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide |
|---|---|
| Synonym | More Synonyms |
Flosulide BiologicalActivity
| Description | Flosulide is a potent and selective COX-2 inhibitor, used for the treatment for inflammatory diseases. |
|---|---|
| Related Catalog | Research Areas >>Inflammation/Immunology |
| Target | COX-2 |
| In Vitro | Flosulide (1 nM-100 μM) causes a concentration-dependent and finally complete inhibition of PGE2 production in the OSC-2 cell line, but with no effect on PG formation in the OSC-1 cells. Flosulide completely suppresses mitotic activity of OSC-2 cells, whereas mitotic activity of OSC-1 cells remain unchanged[2]. |
| In Vivo | In normovolemic rats, flosulide increases renal plasma flow (RPF) and and glomerular filtration rate (GFR). In hypovolemic rats, flosulide (5-25 mg/kg) reduces RPF and GFR. Flosulide at 5 mg/kg reduces 6-keto-PGF1alpha whereas at 25 mg/kg and after indomethacin at 10 mg/kg a fall in 6-keto-PGF1alpha and TXB2 appeares[1]. Flosulide (0.75 mg/day) significantly reduces proteinuria as compared to aspirin treatment. Plasma protein and albumin levels are significantly lower in the aspirin-treated group than in flosulide-treated rats[3]. |
| Cell Assay | The proliferation of the esophageal tumor cell lines is determined using the cell proliferation kit II. Tumor cells are incubated with flosulide and NS-398 at different concentrations for 48 h in DMEM containing FCS (10%), penicillin (100 units/mL), and streptomycin (0.1 mg/mL). After this time, the XTT labeling mixture is added, followed by 4 h of incubation and measurement of absorbance at 490 nm. |
| References | [1]. Turull A, et al. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats. Inflammation. 2001 Apr;25(2):119-28. [2]. Zimmermann KC, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999 Jan 1;59(1):198-204. [3]. Heise G, et al. Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Nephron. 1998 Oct;80(2):220-6. |
Chemical & Physical Properties
| Density | 1.506g/cm3 |
|---|---|
| Boiling Point | 446.9ºC at 760 mmHg |
| Molecular Formula | C16H13F2NO4S |
| Molecular Weight | 353.34100 |
| Flash Point | 224.1ºC |
| Exact Mass | 353.05300 |
| PSA | 80.85000 |
| LogP | 4.41130 |
| Index of Refraction | 1.62 |
| InChIKey | CXJONBHNIJFARE-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)Nc1cc2c(cc1Oc1ccc(F)cc1F)C(=O)CC2 |
| Storage condition | 2-8℃ |
Synonyms
| n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydro-1h-inden-5-yl]methanesulfonamide |
| N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide |
| 6-(2,4-difluorophenoxy)-5-methylsulfonylamino-1-indanone |
| 5-methanesulfonamido-6-((2,4-difluorophenyl)oxy)-1-indanone |
| Flosulida [INN-Spanish] |
| Flosulidum |
| N-[6-(2,4-Difluoro-phenoxy)-1-oxo-indan-5-yl]-methanesulfonamide |
| Flosulidum [INN-Latin] |
| N-(6-(2,4-Difluorophenoxy)-1-oxo-5-indanyl)methanesulfonamide |
| Flosulide |
| Flosulida |
